

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6110589

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRIAN JOHN DOBKOWSKI	11/27/2018
SHENG MENG	12/27/2018
WENHUI SONG	12/28/2018
XIAOXIA YANG	12/14/2018
WEI ZHAO	12/14/2018
RECEIVING PARTY DATA	
Name:	CONOPCO, INC., D/B/A UNILEVER
Street Address:	800 SYLVAN AVENUE
City:	ENGLEWOOD CLIFFS
State/Country:	NEW JERSEY
Postal Code:	07632
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16764953
CORRESPONDENCE DATA	
Fax Number:	(203)381-3822
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2033815327
Email:	PATENTGROUPUS@UNILEVER.COM
Correspondent Name:	KAY ROBERTS
Address Line 1:	40 MERRITT BOULEVARD
Address Line 2:	C/O UNILEVER PATENT GROUP ROOM 130
Address Line 4:	TRUMBULL, CONNECTICUT 06611
ATTORNEY DOCKET NUMBER:	J8827USW1
NAME OF SUBMITTER:	KAY ROBERTS
SIGNATURE:	/Kay Roberts/
DATE SIGNED:	05/18/2020
This document serves as an Oath/Declaration (37 CFR 1.63).	

Total Attachments: 8

source=J8827USw1-DecAssgn#page1.tif

source=J8827USw1-DecAssgn#page2.tif

source=J8827USw1-DecAssgn#page3.tif

source=J8827USw1-DecAssgn#page4.tif

source=J8827USw1-DecAssgn#page5.tif

source=J8827USw1-DecAssgn#page6.tif

source=J8827USw1-DecAssgn#page7.tif

source=J8827USw1-DecAssgn#page8.tif

J8827WO1

DECLARATION / ASSIGNMENT - STATEMENT

WHEREAS, I/We,

DOBKOWSKI Brian John, with Residence address at: Milford, US and Mailing Address at Conopco Inc., d/b/a UNILEVER, 40 Merritt Boulevard, Trumbull, Connecticut, 06611, United States of America.

MENG Sheng, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 LinXin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

SONG Wenhui, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 LinXin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

YANG Xiaoxia, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 Linxin Road, Linkong Economic Development Zone, Shanghai, 200335, China

ZHAO Wei, with Residence address at: Shanghai, CN and Mailing Address at Unilever China (Investing) Company, 66 Linxin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

invented certain improvements in:

COSMETIC COMPOSITIONS COMPRISING SILICONE ELASTOMER AND EMOLLIENT

which is found in:

- a patent application, attached hereto, said application being identified as Unilever Case No. _____;
OR
 International Application No. PCT/EP2018/081775 filed on 2018-11-19 ("the Filing Date");

I. DECLARATION of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America:

- (a) This declaration is directed to the above-identified international application of which it forms a part (if filing declaration with application)
OR
(b) This declaration is directed to the above-identified international application (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby declare that the above-identified international application was made or authorized to be made by me.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

My signature is set forth at the end of this statement.

II. DUTY OF DISCLOSURE

I/We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; and

J8827WO1

I/We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

III. ASSIGNMENT

WHEREAS, Conopco, Inc., d/b/a UNILEVER, a corporation of New York, having a place of business at 800 Sylvan Avenue, Englewood Cliffs, New Jersey 07632 desires to acquire the entire right, title and interest in and to the aforesaid application (the "Application") and in and to the invention(s) therein disclosed for the United States (herein understood to include its possessions and territories).

NOW, THEREFORE, in consideration of one dollar (\$1.00) to each of the undersigned in hand paid and other good and valuable executed consideration, the receipt and sufficiency of all of which is hereby acknowledged, I/We, the undersigned, intending to be legally bound, hereby agree to sell, assign, transfer and convey and hereby do sell, assign, transfer, and convey unto said Conopco, Inc., d/b/a UNILEVER, a corporation of New York, having a place of business at 800 Sylvan Avenue, Englewood Cliffs, New Jersey 07632, its successors and assigns, the entire right, title and interest in and to the invention(s) disclosed in the Application in and for the United States, and in and to the Application and any and all divisional, continuation, continuation-in-part, substitute or other applications in the United States describing said invention(s) or improvements thereon (including the right to claim foreign and/or domestic priority of any of application(s) describing said inventions), and in and to any and all Letters Patent of the United States which may issue from any of the foregoing applications, including any and all extensions, renewals and reissues thereof, the same to be held by and for the sole and exclusive use and benefit of the said Conopco, Inc., d/b/a UNILEVER, its successors and assigns.

AND I/We do hereby authorize and request the Commissioner of Patents to issue the said Letters Patent of the United States to said Conopco, Inc., d/b/a UNILEVER, as the assignee of the entire right, title and interest in and to the same.

AND I/We do hereby agree to assist said Conopco, Inc., d/b/a UNILEVER in the prosecution of any and all said applications and in the prosecution and/or defense of any and all post-grant or other proceedings which may arise involving said invention, and to execute and deliver any powers of attorney, affidavits, assignments, applications, reissues, documents, or other written instruments which, in the opinion of counsel for said, Conopco, Inc., d/b/a UNILEVER, its successors and assigns, may be necessary to secure to said, Conopco, Inc., d/b/a UNILEVER, its successors and assigns, any and all said applications, inventions, improvements, Letters Patent, rights, titles and interests hereby sold, assigned, transferred and conveyed.

This Assignment is effective as of the Filing Date.

My/Our signature below is applicable to all pages above, setting out the Declaration, Duty of Disclosure and the Assignment descriptions and obligations:

J8827W01

Dated: _____

Brian John DOBKOWSKI

Dated: 27 Dec. 2018

Sheng MENG 孟晟
Sheng MENG

Dated: 28 Dec. 2018

Wenhui Song 宋文辉
Wenhui SONG

Dated: 14 Dec. 2018

Xiaoxia Yang 杨晓霞
Xiaoxia YANG

Dated: 14 Dec. 2018

Wei Zhao 赵蔚
Wei ZHAO

u

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

DECLARATION / ASSIGNMENT - STATEMENT

WHEREAS, I/We,

DOBKOWSKI Brian John, with Residence address at: Milford, US and Mailing Address at Conopco Inc., d/b/a UNILEVER, 40 Merritt Boulevard, Trumbull, Connecticut, 06611, United States of America

MENG Sheng, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 LinXin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

SONG Wenhui, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 LinXin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

YANG Xiaoxia, with Residence address at: Shanghai, CN and Mailing Address at Unilever (China) Investing Company, 66 Linxin Road, Linkong Economic Development Zone, Shanghai, 200335, China

ZHAO Wei, with Residence address at: Shanghai, CN and Mailing Address at Unilever China (Investing) Company, 66 Linxin Road, Linkong Economic Development Zone, Changning District, Shanghai, 200335, China

invented certain improvements in:

COSMETIC COMPOSITIONS COMPRISING SILICONE ELASTOMER AND EMOLLIENT

which is found in:

- a patent application, attached hereto, said application being identified as Unilever Case No. _____;
OR
 International Application No. PCT/EP2018/081775 filed on 2018-11-19 ("the Filing Date");

I. DECLARATION of inventorship (Rules 4.17(iv) and 51 bis.1(a)(iv)) for the purposes of the designation of the United States of America:

- (a) This declaration is directed to the above-identified international application of which it forms a part (if filing declaration with application)
OR
(b) This declaration is directed to the above-identified international application (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby declare that the above-identified international application was made or authorized to be made by me.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

My signature is set forth at the end of this statement.

II. DUTY OF DISCLOSURE

I/We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; and

I/We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

III. ASSIGNMENT

WHEREAS, Conopco, Inc., d/b/a UNILEVER, a corporation of New York, having a place of business at 800 Sylvan Avenue, Englewood Cliffs, New Jersey 07632 desires to acquire the entire right, title and interest in and to the aforesaid application (the "Application") and in and to the invention(s) therein disclosed for the United States (herein understood to include its possessions and territories).

NOW, THEREFORE, in consideration of one dollar (\$1.00) to each of the undersigned in hand paid and other good and valuable executed consideration, the receipt and sufficiency of all of which is hereby acknowledged, I/We, the undersigned, intending to be legally bound, hereby agree to sell, assign, transfer and convey and hereby do sell, assign, transfer, and convey unto said Conopco, Inc., d/b/a UNILEVER, a corporation of New York, having a place of business at 800 Sylvan Avenue, Englewood Cliffs, New Jersey 07632, its successors and assigns, the entire right, title and interest in and to the invention(s) disclosed in the Application in and for the United States, and in and to the Application and any and all divisional, continuation, continuation-in-part, substitute or other applications in the United States describing said invention(s) or improvements thereon (including the right to claim foreign and/or domestic priority of any of application(s) describing said inventions), and in and to any and all Letters Patent of the United States which may issue from any of the foregoing applications, including any and all extensions, renewals and reissues thereof, the same to be held by and for the sole and exclusive use and benefit of the said Conopco, Inc., d/b/a UNILEVER, its successors and assigns.

AND I/We do hereby authorize and request the Commissioner of Patents to issue the said Letters Patent of the United States to said Conopco, Inc., d/b/a UNILEVER, as the assignee of the entire right, title and interest in and to the same.


AND I/We do hereby agree to assist said Conopco, Inc., d/b/a UNILEVER in the prosecution of any and all said applications and in the prosecution and/or defense of any and all post-grant or other proceedings which may arise involving said invention, and to execute and deliver any powers of attorney, affidavits, assignments, applications, reissues, documents, or other written instruments which, in the opinion of counsel for said, Conopco, Inc., d/b/a UNILEVER, its successors and assigns, may be necessary to secure to said, Conopco, Inc., d/b/a UNILEVER, its successors and assigns, any and all said applications, inventions, improvements, Letters Patent, rights, titles and interests hereby sold, assigned, transferred and conveyed.

This Assignment is effective as of the Filing Date.

My/Our signature below is applicable to all pages above, setting out the Declaration, Duty of Disclosure and the Assignment descriptions and obligations:

J8827WO1

Dated: 11/27/18


Brian John DOBKOWSKI

Dated: _____

Sheng MENG

Dated: _____

Wenhui SONG

Dated: _____

Xiaoxia YANG

Dated: _____

Wei ZHAO

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent. The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.